José Baselga, M.D., Ph.D.
José Baselga is the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weil Cornell Medical College. His long standing research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 350 peer-reviewed publications to date. Prior to MSK, Dr. Baselga was the Chief of the Division of Hematology / Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He was also the Chairman of Medical Oncology and Founding Director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. Dr. Baselga is the President of the American Association of Cancer Research (AACR), a past President of the European Society for Medical Oncology, and a past member of the Board of Directors for the American Society of Clinical Oncology and AACR. He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and a Fellow of the AACR Academy. He is a past member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, Clinical Cancer Research and is the founding editor-in-chief for the AACR flagship journal Cancer Discovery.
Dr. Baselga received his medical degree from the Universidad Autonoma of Barcelona in 1982. He did his Internal Medicine Residency at both Vall d’Hebron University Hospital in Barcelona, Spain and the State University of New York in the US. He completed a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Baselga has published more than 300 peer-reviewed articles and 400 abstracts and book chapters in his career.
Jeffrey Berkowitz is Executive Vice President at UnitedHealth Group. He was formerly Executive Vice President of Walgreens Boots Alliance, Inc. and President of Pharma and Global Market Access. Previously he was Co-President of Walgreens Boots Alliance Development GmbH since January 2013. Prior to taking on this role, Berkowitz served as the senior vice president, Pharmaceutical Development and Market Access of Walgreens from September 2010 to January 2013. Prior to joining Walgreens, Berkowitz served as senior vice president of global market access for Merck & Company, Inc. upon its acquisition of Schering-Plough in November 2009. From 1998 to 2009, Berkowitz held a variety of positions with increasing responsibility in market access, sales and marketing as well as in the Law Department with Schering-Plough.
Mr. Berkowitz earned his bachelor’s degree in political science from Union College in Schenectady, N.Y., and his Juris Doctor from Brooklyn Law School in Brooklyn, N.Y. He has been recognized three times in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2009, 2010 and 2012, is a member of the Board of Directors of the Swiss American Chamber of Commerce and serves on the Editorial Advisory Board of Pharmaceutical Commerce Magazine.
Anthony Evnin, Ph.D.
Anthony Evnin, Ph.D., lead outside director for Infinity and chair of Infinity’s Nominating and Governance Committee, has been a Partner of Venrock, a venture capital firm, since 1975. Dr. Evnin currently serves on the Board of Directors of AVEO Pharmaceuticals and Juno Therapeutics as well as on the Board of one private company, Constellation Pharmaceuticals. He is a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and a Trustee Emeritus of Princeton University. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Michael Kauffman, M.D., Ph.D.
Michael Kauffman, M.D., Ph.D., co-founded Karyopharm Therapeutics, a publicly traded pharmaceutical company, in 2008 and has served as its Chief Executive Officer and acting Chief Medical Officer since January 2011. Dr. Kauffman was Chief Medical Officer at Onyx Pharmaceuticals Inc., a publicly traded biopharmaceutical company, from November 2009 to December 2010, and was Chief Medical Officer at Proteolix Inc. from November 2008 to November 2009 when it was acquired by Onyx. At Proteolix, he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma by the FDA in July 2012. Dr. Kauffman was an operating partner at Bessemer Venture Partners from 2006 to 2008, where he led investments in biotechnology companies. From 2006 to 2008, he was President and Chief Executive Officer of Epix Pharmaceuticals, Inc., a biopharmaceutical company that underwent liquidation proceedings through an assignment for the benefit of creditors under Massachusetts law in 2009. Dr. Kauffman was President and Chief Executive Officer of Predix Pharmaceuticals, Inc., a private biopharmaceutical company focused on G protein-coupled receptors (GPCR), from 2002 until its merger into Epix Pharmaceuticals in 2006. In that role, he led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, oversaw the discovery and development of four new clinical candidates and led collaboration transactions with Amgen and GlaxoSmithKline. From March 2000 to September 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, where he led the VELCADE® development program. From September 1997 to March 2000, Dr. Kauffman held a number of senior positions at Millennium Predictive Medicine, Inc., a biopharmaceutical company and a subsidiary of Millennium Pharmaceuticals, where he led the discovery and development of novel molecular diagnostics for major cancers, including melanoma, and led transactions with Becton-Dickenson and Bristol Myers Squibb. From August 1995 to September 1997, Dr. Kauffman held a number of senior positions at Biogen Idec, Inc., a biopharmaceutical company, where he led the clinical development of anti-CD40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group. Dr. Kauffman currently serves on the board of directors of Kayropharm, Verastem, Inc., a publicly traded biopharmaceutical company, Excision Biotherapeutics, a privately held biotechnology company, and Kezar Life Sciences, a privately held biotechnology company. Dr. Kauffman previously served on the board of directors of the following companies during the last five years: Zalicus, a privately held biotechnology company, and Metamark Genetics, a privately held molecular diagnostic company.
Dr. Kauffman received his B.A. in Biochemistry from Amherst College and his M.D. and Ph.D. from Johns Hopkins Medical School. Currently board certified in internal medicine, he trained in internal medicine and rheumatology at Beth Israel Deaconess Medical Center and Massachusetts General Hospitals.
Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Prior to becoming Infinity’s chief executive officer, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer.
Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Boards of BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, Bruker Corporation; and is the Vice Chairman of the Board of Project Hope, a multi-service agency committed to breaking the cycle of homelessness and poverty. She is a past member of the Boards of Padlock Therapeutics and the Massachusetts Life Science Center.
Norman Selby has been active in the healthcare world as a consultant, executive, investor and board member for 30+ years. He is currently Executive Chairman of Real Endpoints llc, an information and analytics company focused on pharmaceutical reimbursement and pricing. He served as Chairman of Physicians Interactive Inc. from 2008 – 2013, when it was sold to Merck. Previously Mr. Selby was president and chief executive officer of TransForm Pharmaceuticals, Inc., a specialty pharmaceutical company which was acquired by Johnson & Johnson, and an executive vice president at Citigroup/Citicorp from 1997 to 2000. Mr. Selby spent most of his career at McKinsey & Company, where he was a senior partner and head of the firm’s Global Pharmaceuticals and Medical Products practice. Mr. Selby serves on the Board of Trustees of the Central Park Conservancy, the Memorial Sloan-Kettering Cancer Center and the National Parks Conservation Association. In addition, he serves on the Board of Directors for Metamark Genetics and Merz Group GmbH. He is also a member of the advisory board of the Harvard Business School’s Healthcare Initiative. Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.
Ian Smith, chair of Infinity’s Audit Committee, is executive vice president, chief operating and chief financial officer at Vertex Pharmaceuticals Incorporated. He joined Vertex in November 2001. As Vertex’s Executive Vice President and Chief Financial Officer. Mr. Smith holds responsibility for core functions at Vertex, including Finance and Accounting, Investor Relations, Business Development, Information Systems and Worldwide Operations. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith is also a member of the Board of Directors of Acorda Therapeutics and Ophthotech Corporation and serves as the Chairman of the Audit Committee for Ophthotech. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University, and Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute.
Michael Venuti, Ph.D.
Michael Venuti, Ph.D., chair of Infinity’s Research and Development Committee, is a consultant on drug discovery and development to biotechnology companies and venture capital groups. Previously, he was chief scientific officer of NeuroTherapeutics Pharma, from July 2011 to June 2013. From June 2010 to April 2011, Dr. Venuti served as president and chief executive officer of iPierian, Inc., a private biopharmaceutical company, after joining the company as president and chief scientific officer in February 2010. Prior to joining iPierian, Dr. Venuti served as chief executive officer and member of the board of directors of BioSeek, Inc., which was acquired by Asterand plc in February 2010. He previously served as chief executive officer and member of the board of directors of Discovery Partners International, a small molecule-based drug discovery services company. Dr. Venuti led the merger of Discovery Partners into Infinity Pharmaceuticals in 2006. From 2001 through 2005, he held positions as senior vice president, business development and Pharmacogenomics, and senior vice president, research and preclinical development at Celera Genomics, and served as the general manager of Celera South San Francisco. He served as senior vice president, research and preclinical development, at Axys Pharmaceuticals prior to its acquisition by Celera. Prior to joining Axys, Dr. Venuti was director of Bioorganic Chemistry at Genentech, Inc., and began his research career in medicinal chemistry at Syntex Research. Dr. Venuti holds an A.B. from Dartmouth College, and a Ph.D. in Organic Chemistry from The Massachusetts Institute of Technology.